ELOVERA IMF

Main information

  • Trade name:
  • ELOVERA IMF 50GM CRM
  • Pharmaceutical form:
  • CRM
  • Composition:
  • 50GM
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ELOVERA IMF 50GM CRM
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

27-7-2018

Pending EC decision:  Imfinzi, durvalumab, Opinion date: 26-Jul-2018

Pending EC decision: Imfinzi, durvalumab, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

25-9-2018

Imfinzi (AstraZeneca AB)

Imfinzi (AstraZeneca AB)

Imfinzi (Active substance: durvalumab) - Centralised - Authorisation - Commission Decision (2018)6289 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004771/0000

Europe -DG Health and Food Safety